$11.00
0.00%
Nasdaq, Wed, Dec 24 2025
ISIN
US30049G1040
Symbol
EVOK

Evoke Pharma, Inc. Stock price

$11.00
+0.27 2.52% 1M
+8.24 298.55% 6M
+6.58 148.87% YTD
+6.10 124.49% 1Y
-20.44 65.01% 3Y
-393.64 97.28% 5Y
-459.88 97.66% 10Y
-1,679.56 99.35% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
+0.00 0.00%
ISIN
US30049G1040
Symbol
EVOK
Industry

Key metrics

Basic
Market capitalization
$19.0m
Enterprise Value
$12.4m
Net debt
positive
Cash
$11.6m
Shares outstanding
1.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
1.3 | 1.2
EV/Sales
0.9 | 0.8
EV/FCF
negative
P/B
5.6
Financial Health
Equity Ratio
40.2%
Return on Equity
-76.1%
ROCE
-152.3%
ROIC
-
Debt/Equity
1.5
Financials (TTM | estimate)
Revenue
$14.4m | $16.3m
EBITDA
- | -
EBIT
$-5.2m | $-4.9m
Net Income
$-5.2m | $-3.3m
Free Cash Flow
$-3.3m
Growth (TTM | estimate)
Revenue
67.3% | 59.0%
EBITDA
- | -
EBIT
12.0% | 5.4%
Net Income
15.0% | 38.3%
Free Cash Flow
37.6%
Margin (TTM | estimate)
Gross
97.0%
EBITDA
- | -
EBIT
-36.0%
Net
-36.2% | -20.2%
Free Cash Flow
-23.1%
More
EPS
$-2.0
FCF per Share
$-1.9
Short interest
0.5%
Employees
3
Rev per Employee
$3.4m
Show more

Is Evoke Pharma, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Evoke Pharma, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Evoke Pharma, Inc. forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a Evoke Pharma, Inc. forecast:

Hold
50%
Sell
50%

Financial data from Evoke Pharma, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
14 14
67% 67%
100%
- Direct Costs 0.43 0.43
43% 43%
3%
14 14
68% 68%
97%
- Selling and Administrative Expenses 19 19
35% 35%
133%
- Research and Development Expense 0.06 0.06
50% 50%
0%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -5.19 -5.19
12% 12%
-36%
Net Profit -5.23 -5.23
15% 15%
-36%

In millions USD.

Don't miss a Thing! We will send you all news about Evoke Pharma, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Evoke Pharma, Inc. Stock News

Neutral
PRNewsWire
9 days ago
Evoke Stockholders Received $11.00 Per Share in Cash SOLANA BEACH, Calif., and VERO BEACH, Fla.
Negative
Proactive Investors
16 days ago
Shares in William Hill owner Evoke PLC (LSE:EVOK) bounced 8% to 23.83p after the bookmaker confirmed that it is putting all or part of the company up for sale. A strategic review has been launched, the company said in a short statement, including "a range of potential alternatives to maximise shareholder value, including, but not limited to a potential sale of the group, or some of the company'...
Negative
Proactive Investors
29 days ago
Bookmakers Entain PLC (LSE:ENT), Evoke PLC (LSE:EVOK) and Flutter Entertainment PLC (LSE:FLTR, NYSE:FLUT) have warned investors of "highly damaging" consequences from the new UK gambling tax measures in yesterday's Budget, which are set to come into force from next April. Under changes announced in the autumn Budget, online gaming duty will rise to 40% from April 2026, and a new 25% remote bett...
More Evoke Pharma, Inc. News

Company Profile

Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. It develops Gimoti, with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The company was founded by Matthew J. D'Onofrio, Cam L. Garner, Scott L. Glenn, and David A. Gonyer in January 2007 and is headquartered in Solana Beach, CA.

Head office United States
CEO Matthew D'Onofrio
Employees 3
Founded 2007
Website evokepharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today